• Robert J. Battat, MD, Centre Hospitalier de l'Universite de Montreal
• David Ziring, MD, Cedars Sinai
Maximizing Biologic Response
& Drug Persistence
Are loss of response and biologic failure unavoidable? Advances in patient-specific biologic optimization via precision-guided dosing are fundamentally altering the IBD treatment landscape. During this presentation published studies and case reviews will demonstrate how this paradigm shifting approach is empowering data-driven treatment decisions, enhancing drug durability, and ushering in a new era of personalized care.
Please select the presentation(s) you are interested in:(Check all of interest)
for Every Patient
Upon registering, you will receive an email confirmation with a calendar invitation and will be notified when the series recordings are available on demand.
The IBD treatment paradigm continues to evolve in support of early treatment optimization and tight disease monitoring. During this series, experts will review both published studies and case reviews that support the clinical utility of applying individualized precision to patient care.
This presentation is not intended or eligible for continuing education (CME/CE) credits and does not meet guidelines governing CME/CE. This material is provided for general informational purposes only, as an educational service for healthcare providers. It is not intended as a substitute for medical advice and/or consultation with a physician. All expert speakers are being compensated by Prometheus Laboratories for this program. Prometheus is a registered trademark of Prometheus Laboratories Inc. All other trademarks and service marks are the property of their respective owners.©2023 Prometheus Laboratories Inc.; all rights reserved.
• Bincy Abraham, MD, Houston Methodist Hospital
• Ronen Arai, MD, Gastro Health Medical Group
Explore the transformative impact precision-guided dosing is having on everyday clinical decisions. Precision-guided dosing aids in early treatment optimization and may decrease health care expenditures by expediently optimizing dosing, reducing unnecessary biologic use, avoiding disease-related adverse outcomes, and enhancing the durability of response. In this presentation, attendees can expect real-life examples demonstrating the clinical utility of precision-guided dosing when incorporating this personalized approach into their practice of managing their patients with IBD.